04.08.2025, 20:25
Russian pharmaceutical company fined for advertising at music festival
Source: OREANDA-NEWS
OREANDA-NEWS The pharmaceutical company Geropharm was fined 200,000 rubles for advertising the prescription drug Semavik at the New Wave 2024 music festival and the Hello magazine gala dinner. This is reported on the website of the Office of the Federal Antimonopoly Service for the Moscow Region.
According to the antimonopoly authorities, the advertising organized by the company during these events violated the requirements of the relevant legislation.
As the authors of the relevant resolution recalled, in accordance with part 8 of Article 24 of the Law on Advertising, advertising of medicines in prescription forms and dosages is not allowed except in venues of medical or pharmaceutical exhibitions, seminars, conferences and other similar events and in specialized print media intended for medical and pharmaceutical workers.. However, the New Wave 2024 music festival and the Hello magazine gala dinner cannot be considered such events.
At the end of May, it became known that the Federal Antimonopoly Service of Russia had fined the pharmaceutical company KRKA. The reason was the monopolistically high prices for individual dosages of the drug Ko-Dalneva.
According to the antimonopoly authorities, the advertising organized by the company during these events violated the requirements of the relevant legislation.
As the authors of the relevant resolution recalled, in accordance with part 8 of Article 24 of the Law on Advertising, advertising of medicines in prescription forms and dosages is not allowed except in venues of medical or pharmaceutical exhibitions, seminars, conferences and other similar events and in specialized print media intended for medical and pharmaceutical workers.. However, the New Wave 2024 music festival and the Hello magazine gala dinner cannot be considered such events.
At the end of May, it became known that the Federal Antimonopoly Service of Russia had fined the pharmaceutical company KRKA. The reason was the monopolistically high prices for individual dosages of the drug Ko-Dalneva.
Комментарии